| Setting | Studie | Phase | Einschlusskriterien | Intervention |
| NSCLC, Early Stage, neoadjuvant | INN-WOP | Phase II, single-arm | NSCLC; T≥1.5cm, primär operabel | Neoadjuvant, 2x Pembrolizumab + Lenvatinib neoadjuvant |
| NSCLC, Early Stage, adjuvant nach neoadjuvant KN671 Schema | MK2870-019 | Phase III | NSCLC; Stage II-IIIB; keine pCR nach neoadjuvant KN671 | Adjuvant: Pembrolizumab + MK2870 (TROP2-ADC) vs. Pembrolizumab |
| NSCLC, Metastatic, First-Line | TROPION-Lung10 | Phase III | NSCLC, Stage ≥IIIB, nicht squamös, PD-L1 ≥50% | Datopotamab-Deruxtecan (TROP2-ADC) + Rilvegostimig (PD-1 und TIGIT bispecific AK) vs. Rilvegostomig vs. Pemrolizumab |
| NSCLC, Metastatic, First-Line | LUNAR-2 | Phase III | NSCLC, metastatic | Tumor Treating fields (TTF) + Pembrolizumab/Platin-doublet vs. Pembrolizumab/Platin-doublet |
| NSCLC, Metastatic, Second-Line, IO Progression | LUNAR-4 | Phase II | NSCLC, IO-Progression | Tumor Treating fields (TTF) + Pembrolizumab |
| NSCLC, Metastatic, First-Line | AMG20230167 | Phase Ib/II | NSCLC mit MTAP-Deletion | AMG193 (methylthioadenosine (MTA)- cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor) + Standard of Care |
| Metastatic, heavy pretreated | BI1456-0001 | Phase I | heavy pretreated | BI 1831169 (onkolytischer RNA Virus) + Checkpoint Inhibitor |
| Metastatic, heavy pretreated | PALINDROM | Phase I | heavy pretreated | APN401-104 (PBMC basierte Leukozyten Immuntherapie) |
| Metastatic, heavy pretreated | SOUND | prospectiv | Heavy pretreated | Comprehensive genomic tumour profiling including liquid biopsy |
